Please login to the form below

Not currently logged in
Email:
Password:

pancreatic cancer

This page shows the latest pancreatic cancer news and features for those working in and with pharma, biotech and healthcare.

Trial backs role for Lynparza in second-line prostate cancer

Trial backs role for Lynparza in second-line prostate cancer

It already has approval for ovarian and breast cancer and has also shown a benefit in late-stage data in  pancreatic cancer, again the first in its class to do so. ... Prostate cancer is the second-most common cancer in men, with an estimated 1.3

Latest news

More from news
Approximately 23 fully matching, plus 108 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies.

  • Finding the patient voice Finding the patient voice

    Mr Whitley took part in a pancreatic cancer drug trial in 2011.

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.  . ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex, goserelin acetate implant for prostate, breast cancer,

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    1. MM-398 a nanoliposomal irinotecan injection of for metastatic pancreatic cancer in phase III. ... 805. Curevac / Boehringer Ingelheim. Licence and collaboration. Messenger RNA vaccine (CV9202) in combination with afatininib and chemo-radiation for

  • Pharma deals during September 2014 Pharma deals during September 2014

    Baxter is licensing Merrimack's nanoliposomal injection of irinotecan which has orphan status in the US and the EU for metastatic pancreatic cancer, but does not have US rights. In contrast,

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics